Published in Ann Neurol on July 01, 2001
Brain Peripheral Benzodiazepine Receptors in Patients With Multiple Sclerosis | NCT00432900
Interferon ß-1b Treatment by Cyclical Administration | NCT00270816
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet (2009) 4.97
Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS. Neurology (2013) 4.60
Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med (2011) 4.02
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet (2008) 3.93
Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol (2008) 3.92
Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature (2010) 3.90
Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology (2011) 3.62
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain (2008) 3.05
Accuracy of magnetic resonance imaging for the diagnosis of multiple sclerosis: systematic review. BMJ (2006) 2.95
Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology (2013) 2.77
CD226 Gly307Ser association with multiple autoimmune diseases. Genes Immun (2008) 2.76
Evidence for polygenic susceptibility to multiple sclerosis--the shape of things to come. Am J Hum Genet (2010) 2.64
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology (2009) 2.58
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol (2011) 2.55
A high-density screen for linkage in multiple sclerosis. Am J Hum Genet (2005) 2.50
Ganglion cell loss in relation to visual disability in multiple sclerosis. Ophthalmology (2012) 2.48
Multiple sclerosis. J Clin Invest (2004) 2.48
A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis. Neurology (2014) 2.45
Intellectual enrichment lessens the effect of brain atrophy on learning and memory in multiple sclerosis. Neurology (2010) 2.45
The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol (2005) 2.44
Multiple sclerosis. J Clin Invest (2012) 2.41
Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study. PLoS Med (2015) 2.40
The role of the CD58 locus in multiple sclerosis. Proc Natl Acad Sci U S A (2009) 2.38
Diffusion tensor imaging of post mortem multiple sclerosis brain. Neuroimage (2006) 2.35
MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology (2010) 2.33
A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology (2010) 2.30
HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology (2010) 2.29
High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. JAMA Neurol (2015) 2.23
Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nat Clin Pract Neurol (2008) 2.20
Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging. J Magn Reson Imaging (2009) 2.17
The expanding genetic overlap between multiple sclerosis and type I diabetes. Genes Immun (2008) 2.17
MRI of the corpus callosum in multiple sclerosis: association with disability. Mult Scler (2010) 2.13
MRI in multiple sclerosis: current status and future prospects. Lancet Neurol (2008) 2.08
Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol (2013) 2.08
HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PLoS One (2007) 2.05
The sad plight of multiple sclerosis research (low on fact, high on fiction): critical data to support it being a neurocristopathy. Inflammopharmacology (2010) 2.05
Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology (2011) 2.02
A second major histocompatibility complex susceptibility locus for multiple sclerosis. Ann Neurol (2007) 1.99
Differential micro RNA expression in PBMC from multiple sclerosis patients. PLoS One (2009) 1.98
Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. Eur J Hum Genet (2009) 1.97
Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest (2005) 1.95
Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci U S A (2004) 1.91
In vivo magnetic resonance imaging of acute brain inflammation using microparticles of iron oxide. Nat Med (2007) 1.90
IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci. Genes Immun (2010) 1.83
Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci U S A (2004) 1.80
Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci. Hum Mol Genet (2009) 1.80
Axonal injury detected by in vivo diffusion tensor imaging correlates with neurological disability in a mouse model of multiple sclerosis. NMR Biomed (2008) 1.78
Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler (2012) 1.77
Detection of human herpesvirus-6 in cerebrospinal fluid of patients with encephalitis. Ann Neurol (2009) 1.75
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol (2016) 1.73
The complex genetics of multiple sclerosis: pitfalls and prospects. Brain (2008) 1.68
Leptin increase in multiple sclerosis associates with reduced number of CD4(+)CD25+ regulatory T cells. Proc Natl Acad Sci U S A (2005) 1.67
An RCT to treat learning impairment in multiple sclerosis: The MEMREHAB trial. Neurology (2013) 1.64
In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI. Neurology (2009) 1.64
Diagnosis and treatment of multiple sclerosis. BMJ (2006) 1.61
Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy. Neurology (2016) 1.61
Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med (2007) 1.61
Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation (2010) 1.60
Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry (2005) 1.59
A gradient in cortical pathology in multiple sclerosis by in vivo quantitative 7 T imaging. Brain (2015) 1.59
A population-based study of neuromyelitis optica in Caucasians. Neurology (2011) 1.58
Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler (2014) 1.56
Multifactor dimensionality reduction reveals gene-gene interactions associated with multiple sclerosis susceptibility in African Americans. Genes Immun (2006) 1.56
Spinal cord repair in MS: does mitochondrial metabolism play a role? Neurology (2010) 1.56
Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J Immunol (2009) 1.55
Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis. Prog Neurobiol (2010) 1.54
Quantitative magnetization transfer imaging in postmortem multiple sclerosis brain. J Magn Reson Imaging (2007) 1.54
Warmer outdoor temperature is associated with worse cognitive status in multiple sclerosis. Neurology (2012) 1.53
Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol (2013) 1.52
Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance. J Neuroinflammation (2012) 1.52
Neurology training in the United Kingdom: a diagnostic analysis of over 5000 patients. J Neurol (2005) 1.52
Cortical atrophy is relevant in multiple sclerosis at clinical onset. J Neurol (2007) 1.51
CD24 is a genetic modifier for risk and progression of multiple sclerosis. Proc Natl Acad Sci U S A (2003) 1.51
Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol (2009) 1.50
Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol (2011) 1.49
Infection-triggered familial or recurrent cases of acute necrotizing encephalopathy caused by mutations in a component of the nuclear pore, RANBP2. Am J Hum Genet (2009) 1.47
Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol (2008) 1.46
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol (2009) 1.46
Intellectual enrichment is linked to cerebral efficiency in multiple sclerosis: functional magnetic resonance imaging evidence for cognitive reserve. Brain (2009) 1.45
Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis. J Clin Invest (2008) 1.44
Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein. J Immunol (2005) 1.43
Aquaporin 4 molecular mimicry and implications for neuromyelitis optica. J Neuroimmunol (2013) 1.42
Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch Neurol (2009) 1.42
Brain viscoelasticity alteration in chronic-progressive multiple sclerosis. PLoS One (2012) 1.41
Demyelinating diseases. J Clin Pathol (2006) 1.41
Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. J Neurol (2007) 1.41
A 16-year-old boy with progressive central vision loss in his left eye. CMAJ (2004) 1.40
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months. Neurol Neuroimmunol Neuroinflamm (2016) 1.40
Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol (2014) 1.39
Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain (2008) 1.38
Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain (2008) 1.37
Incidence of multiple sclerosis in the United Kingdom : findings from a population-based cohort. J Neurol (2007) 1.37
Cognition in the early stage of multiple sclerosis. J Neurol (2006) 1.37
Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters. PLoS One (2015) 1.36
Magnetic resonance frequency shifts during acute MS lesion formation. Neurology (2013) 1.35
Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol (2013) 1.34
New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol (1983) 26.67
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet (2010) 11.55
Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology (1996) 10.26
Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J Clin Microbiol (2007) 7.30
Structural basis of cell-cell adhesion by cadherins. Nature (1995) 6.56
Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase. Cell (1991) 6.28
Spectrographic data concerning vitamin A and liver oils. Biochem J (1931) 6.14
Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit. Cell (1992) 5.29
X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli. Science (1999) 4.78
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet (2001) 4.55
Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain (1999) 4.41
Immunological aspects of demyelinating diseases. Annu Rev Immunol (1992) 4.39
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology (2006) 4.38
The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med (1993) 4.34
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (2011) 4.25
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med (2000) 3.98
Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency. Neurology (2010) 3.98
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain (1997) 3.87
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Altered electrical properties in Drosophila neurons developing without synaptic transmission. J Neurosci (2001) 3.80
The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler (1999) 3.71
Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol (1999) 3.67
Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nat Med (1997) 3.65
Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest (1994) 3.58
Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol (1992) 3.53
The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain (2001) 3.51
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology (2005) 3.45
Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci U S A (1998) 3.35
Giardia and Cryptosporidium join the 'Neglected Diseases Initiative'. Trends Parasitol (2006) 3.34
A gender gap in autoimmunity. Science (1999) 3.33
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
The crystal structure of dimeric kinesin and implications for microtubule-dependent motility. Cell (1997) 3.17
In vivo measurement of T2 distributions and water contents in normal human brain. Magn Reson Med (1997) 3.11
Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene (2006) 3.09
A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat Genet (1996) 3.00
A full genome search in multiple sclerosis. Nat Genet (1996) 2.96
Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology (2005) 2.95
Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology (1996) 2.94
Body mass index and mortality in 'healthier' as compared with 'sicker' haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant (2001) 2.94
Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology (2007) 2.88
Slow virus replication: the role of macrophages in the persistence and expression of visna viruses of sheep and goats. J Gen Virol (1982) 2.87
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology (2006) 2.75
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 2.66
Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology (2006) 2.64
Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol (1999) 2.61
An activating mutation of AKT2 and human hypoglycemia. Science (2011) 2.60
Structure of a cephalosporin synthase. Nature (1998) 2.59
A population-based study of multiple sclerosis in twins. N Engl J Med (1986) 2.59
Age-dependent resistance to viral encephalitis: studies of infections due to Sindbis virus in mice. J Infect Dis (1972) 2.56
Idiopathic acute transverse myelitis: application of the recent diagnostic criteria. Neurology (2005) 2.53
Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol (1998) 2.47
EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol (2010) 2.45
Provision of treatment for multiple sclerosis. Lancet (1999) 2.44
The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis. Nature (1995) 2.44
Antineutrophil cytoplasmic antibodies, cystic fibrosis, and infection. Lancet (1991) 2.41
La Crosse encephalitis in children. N Engl J Med (2001) 2.38
Corticosteroid-induced suppression of the hypothalamo-pituitary-adrenal axis: observations on patients given oral corticosteroids for rheumatoid arthritis. Q J Med (1967) 2.38
Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology (2002) 2.36
Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology (2002) 2.34
Cause of death in patients attending multiple sclerosis clinics. Neurology (1991) 2.33
Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology (2008) 2.29
Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol (1999) 2.28
Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology (2011) 2.26
Amplification and molecular cloning of HTLV-I sequences from DNA of multiple sclerosis patients. Science (1989) 2.23
Vasopressin administration facilitates fluid removal during hemodialysis. Kidney Int (2006) 2.23
Doppler echocardiographic measurement of low velocity motion of the left ventricular posterior wall. Am J Cardiol (1989) 2.23
Automation of sample mounting for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr (2006) 2.22
Measles virus-specific T4+ human cytotoxic T cell clones are restricted by class II HLA antigens. J Immunol (1984) 2.21
The pathophysiology of HOX genes and their role in cancer. J Pathol (2005) 2.18
Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology (1998) 2.17
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis. Brain (1998) 2.16
Postmortem verification of MS cortical lesion detection with 3D DIR. Neurology (2012) 2.16
Increase of oleic acid in erythrocytes associated with malignancies. Br Med J (Clin Res Ed) (1985) 2.15
Myelin water imaging in multiple sclerosis: quantitative correlations with histopathology. Mult Scler (2006) 2.12
Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease. Nat Med (1999) 2.11
HLA class II-restricted presentation of cytoplasmic measles virus antigens to cytotoxic T cells. J Virol (1989) 2.11
The role of B cells and autoantibodies in multiple sclerosis. Ann Neurol (2000) 2.07
Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J Immunol (1990) 2.07
[Medicinal cannabis for diseases of the nervous system: no convincing evidence of effectiveness]. Ned Tijdschr Geneeskd (2004) 2.03
Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol (1991) 2.00
Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol (1999) 1.99
Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis. Mult Scler (2006) 1.99
Comparison of ultrasound measurements at the heel between adults with mental retardation and control subjects. Bone (1998) 1.97
The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain (1998) 1.96
Multiple sclerosis and human T-cell lymphotropic retroviruses. Nature (1985) 1.96